Targeted gene therapy may reduce AML burden and protect the heart from cardiotoxicity

Eli Lil­ly said Mon­day morn­ing that it has sub­mit­ted an ap­pli­ca­tion for its ex­per­i­men­tal Alzheimer’s drug do­nanemab to the FDA, and ex­pects a de­ci­sion by

VIENNA — New data reported here reinforce the idea that chimeric antigen receptor T-cell (CAR-T) therapy can be an out-and-out cure for many rheumatologic diseases.